Excalipoint Therapeutics closed a $68.7 million financing to advance multi‑platform T‑cell engager programs and a six‑program pipeline, the company said. The round comprised an earlier seed close and a follow‑on extension, with co‑investors including Hongshan Capital, Apricot Capital, Lily Asia Ventures and Eisai’s innovation fund. Excalipoint plans to use proceeds to accelerate clinical development of lead candidates, including ongoing Phase I/II work for EXP011. Coverage positioned the raise as emblematic of China’s capital‑efficient NewCo model that prioritizes rapid clinic‑forward data generation and global partnering options.